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Background: Early diagnosis of chronic obstructive pulmonary disease (COPD) remains the main
intervention to prevent disease progression. However, conflicting results exist on the utility of
two different diagnostic strategies that preclude freely recommending one strategy in favor of
the other. Spirometry was used to determine the effectiveness of a symptom-based (case-
finding) strategy vs. a screening strategy to detect COPD in smokers.
Methods: The case-finding strategy was undertaken during the COPD Day campaign in smokers
with respiratory symptoms who were willing to submit to lung function testing. Screening was
carried out with smokers attending a smoking cessation program. A short standardized ques-
tionnaire on respiratory symptoms along with spirometry were carried out and analyzed for
both strategies.
Results: We evaluated 2781 smokers (mean pack/years 23.38): 1999 from the case-finding
strategy and 782 from the smoking cessation program strategy (SCS). Prevalence of COPD ac-
cording to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria was 10.1
and 13.3%, respectively (p < 0.01). With the exception of dyspnea (70.6% vs. 72.5%, pZ 0.72),c Society; COPD, chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV1,
d; GOLD, global initiative for chronic obstructive lung disease; INER, National Institute of Respiratory
moking Cessation Clinics, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas,
an, CP 14080, Mexico City, Mexico.
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Early diagnosis of COPD 581prevalence of symptoms such as cough (61.5 vs. 37, p < 0.001), phlegm (60.4 vs. 38.2,
p < 0.001) and wheezing (56.7 vs.15.06, p < 0.001) was higher among smokers from the
case-finding strategy. Multivariate logistic regression analysis showed that dyspnea
[ORZ 2.09 (95% CI 1.41e3.1)] was the only common predictor of COPD after jointly and sepa-
rately analyzing case-finding and screening strategies.
Conclusions: For early diagnosis of COPD in a primary care setting, a screening strategy aimed
at all smokers may be more useful than a case-finding strategy.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The impact of chronic obstructive pulmonary disease (COPD)
on morbidity and mortality rate increased during the 1990s
and is predicted to be a major worldwide cause of death
during the following decades.1 Furthermore, these figures
may be considerably higher if the proportion of smokers with
COPD is not 15% but instead 50% as has been suggested.2
Therefore, early diagnosis of COPD is relevant both to
prevent and treat disease progression. However, physicians
do not routinely advise smokers about the importance of
smoking cessation or recommend spirometry testing to
smokers.3e5
The majority of smokers are unaware of the risk of
developing COPD6 and do not recognize symptoms of
respiratory disease; therefore, they do not seek medical
advice. The presence of chronic respiratory symptoms
when used as cues for performing pulmonary function tests
(case-finding strategy) may be useful for early diagnosis of
COPD. The majority of information results from case-
finding studies, with scarce information resulting from
screening studies. In this sense, usefulness of symptoms in
the primary care setting remains an issue with conflicting
results.6e8
Studies on the usefulness of spirometry screening are
scant, probably due to the assumption of low cost-effec-
tiveness.3 Therefore, additional information is needed on
the usefulness of spirometry as a screening device when
smokers are not selected on the basis of symptoms.
In order to determine the usefulness of respiratory
symptoms vs. a screening program for early diagnosis of
COPD, we compared the prevalence according to two
different settings. The first setting included symptomatic
smokers who were undergoing spirometry without cost
(case-finding). The second setting included patients in
whom spirometry was performed as part of a medical
evaluation of a smoking cessation program. An additional
objective was to determine the predictive value of respi-
ratory symptoms such as cough, phlegm, dyspnea and
wheezing in order to establish an early diagnosis of COPD.
Subjects and methods
This study was performed in the COPD and Smoking
Cessation Clinic of the National Institute of Respiratory
Diseases (INER) in Mexico City. INER is a public tertiary-care
center devoted to medical care, teaching, and research,
with a focus on respiratory diseases. The project was
approved by the ethics committee of the INER (Comite´ deCiencia y Bioe´tica en Investigacio´n, approval #C08-05).
Financial considerations for spirometry, technicians and
medical care during the study were supported by a grant
from the research programs of the INER. The mass media
campaign was completely supported by various pharma-
ceutical companies who were willing to cooperate in the
campaign with an unrestricted grant.
Subjects
Participants were required to be current or former smokers
with a cumulative consumption history of at least 10 pack/
years. Additionally, subjects fulfilled the following criteria:
1) have a valid pre- and postbronchodilator spirometry, 2)
complete a symptom questionnaire, 3) no self-report of
previous diagnosis of asthma or other pulmonary diseases
such as bronchiectasis, and 4) no self-report of a history of
exposure to wood smoke or biomass. Subjects were
recruited using the following two approaches: case-finding
and screening all smokers from a smoking cessation
program (SCP screening).
The case-finding strategy was undertaken during the
COPD Day campaign using mass media advertisements
focused on symptomatic smokers (cough, phlegm, wheezing
and shortness of breath) willing to submit to lung function
testing. The COPD Day celebration is a leading campaign
launched by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD).9 Corresponding data from this case-
finding strategy were obtained from the last five COPD
Day campaigns.
The SCP strategy was undertaken with smokers
attending a smoking cessation program. The smoking
cessation clinic is integrated into the facilities of the INER
and offers services and assistance to smokers who wish to
stop smoking. It is an “open program” and most smokers
attending our program are not patients of INER and are in
apparently good health. Those smokers who were aware of
having some type of respiratory disease were excluded
from this protocol.
As part of the smoking cessation program, screening
tests including spirometry were performed and the ques-
tionnaire regarding respiratory symptoms was completed.
All subjects read and signed the “patient information
consent form.”
Questionnaire
A brief questionnaire containing 28 items including age,
gender, smoking status, presence of cough, phlegm,
582 R.H. Sansores et al.wheezing and shortness of breath was completed by all
participants. Shortness of breath was determined by
answering yes or no to the statement: “I experience
shortness of breath when walking quickly on a level surface
or walking up a slight incline,” which corresponds to the
MRC grade 1.10 In order to properly complete the ques-
tionnaire and to assist smokers, a facilitator was available
at all times.
Spirometry
Subjects were submitted to both pre- and post-
bronchodilator spirometry following the procedures rec-
ommended by the American Thoracic Society and the
European Respiratory Society (ATS/ERS)11 with a dry rolling-
seal volume spirometer (Sensormedics; Yorbalinda, CA).
Data were expressed as percent of predicted value using
Mexican values of reference equations of Perez-Padilla.12
Body mass index (BMI) was estimated from weight (kg)
divided by height (m2) of individuals.
COPD was defined in accordance with the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) guide-
lines13 using a fixed FEV1/FVC ratio (<0.70) in long-term
smokers who were >40 years of age. Severity of airway
obstruction was quantified in accordance with GOLD
guidelines.14
Statistical analysis
The general characteristics of the subjects were described
using mean and standard deviations. Between-group
comparisons were made using Student t-test or c2 test for
comparisons between proportions. Multiple linear regres-
sion analysis was used to estimate the relationship between
diagnosis of COPD and symptoms for each strategy indi-
vidually and jointly for the two strategies.
Results
Subjects
There were 2781 smokers included (mean pack/years 23.38);
1999 participants were from the case-finding group (mean
age 53  10 years) and 782 participants from the SCP group
(mean age 47  12 years) from a total of 3878 smokers
evaluated. Fig. 1 summarizes the exclusion criteria.
Table 1 describes general and functional characteristics
of both groups of participants. Subjects from the SCP group
were younger but had a history of heavier smoking (greater
number of pack/years, number of cigarettes smoked per day
and years of smoking) than participants from the case-
finding group. They also had lower FEV1 both in milliliters
(ml) and percent predicted value than subjects from the
case-finding group. Subjects from the SCP group had FVC (in
ml) greater than subjects from the case-finding group,
explaining the lower FEV1/FVC ratio in this group where the
prevalence of COPD was also higher (13.3 vs. 10.1%,
p Z 0.01). The prevalence of COPD according to the lower
limit of normality (LLN) was also higher in the SCP group than
in the case-finding group (11.7% vs. 7.8%, respectively). Onthe contrary, subjects from the case-finding group had more
cough, phlegm, wheezing and history of bronchitis and
emphysema. Dyspnea was the most prevalent symptom and
no differences were found between groups (Table 1). No
association between dyspnea and BMI was found.
When subjects with airflow limitation were analyzed
according to the detection strategy used, differences were
found in pack/years, years of smoking, number of ciga-
rettes/day, FEV1 both in ml and %p, and FVC (ml). No
differences were found according to GOLD stages (Table 2).
A higher percentage of subjects with COPD from the case-
finding group had more symptoms than subjects from the
screening group. The percentage of subjects with dyspnea
was similar in both groups (Table 2).
Table 3 summarizes the factors predicting COPD
according to a multivariate logistic regression analysis. For
this analysis, a pool of the two groups was built. Male
gender, cough, dyspnea and wheezing were risk factors for
COPD, whereas younger age was a protective factor for risk
of COPD. After separately analyzing the strategies for
detection of COPD, only dyspnea remained as a risk factor
for COPD. Wheezing and cough additionally appeared as
risk factors for the development of COPD in the case-finding
and SCP groups, respectively (Table 3).Discussion
The main result of this study is that after all smokers were
screened with spirometry, COPD prevalence was higher
than when subjects were selected according to symptoms.
This difference remained by using either the fixed cut-off of
the FEV1/FVC ratio of 0.70 or the LLN. Whereas symptoms
such as cough, phlegm and wheezing were significantly
more frequent (as expected) in the case-finding group than
in the SCP group, frequency of dyspnea was similar in both
groups (either when analyzed in the general group or in the
group with COPD). In this sense, dyspnea was the only
symptom predicting COPD using either strategy for early
diagnosis.
Diagnosis of COPD remains a challenging issue, particu-
larly in the primary care setting. Although spirometry is
recognized as the “gold standard” for diagnosis of airflow
limitation by most scientific societies,9,13,14 its use is often
limited. One study15 demonstrated that when a diagnosis of
COPD is made in both primary care and subspecialty
settings, spirometry is performed in only one third of the
cases (range: 21e30%) and only less than half of those
included postbronchodilator screening,6,16e20 despite
recommendations proposed in scientific guidelines. For
example, only 12% of the individuals with COPD diagnosed
in the PLATINO study had a diagnosis of COPD during the
previous year of the study. This observation strengthens the
issue that the subdiagnosis may be due to the low number
of spirometries requested for symptomatic subjects or
those who were smokers. This is the main cause of under-
diagnosis of COPD and, consequently, for worldwide
underestimation of its prevalence.
Using spirometry and in order to make an appropriate and
timely diagnosis of COPD in subjects who are smokers, two
strategies have been proposed. The first21 is to screen only
symptomatic smokers using spirometry. The second strategy,
Total number of smokers
 = 3878 
Invited to complete symptom questionnaire
n = 3228 
Completed questionnaires 
 = 3152 
Excluded  = 650 
• Unable to be located = 500 
• Missed = 150  
Excluded = 76
Refused to answer questions 
Excluded = 223
Did not fulfill eligibility 
criteria 
Completed pre- and postbronchodilator spirometry  
n = 2929 
Excluded = 148
Spirometry not performed 
• Did not understand instructions  = 38 
• Excluded for medical reasons  = 17 
• Unable to physically cooperate = 93 
Satisfactory spirometry performed 
= 2781
Case finding 
n = 1999 
COPD 
10.1% 
Smoking Cessation Program group 
 = 782 
COPD
13.3% 
  34 SCP
189 CF 
  48 SCP 
100 CF
SCP. Smoking Cessation Program. 
CF, case finding. 
Figure 1 The majority of excluded subjects were from the case-finding group. For example, the first 650 excluded subjects were
individual who made an appointment after the mass media advertisements. However, they did not attend the appointment and
afterwards were unable to locate them. From the same case-finding group were the 76 subjects who refused to answer the
questionnaire. According to the telephone interview, their ages (of the 650 þ 76 subjects) were similar to the age of those subjects
of the case-finding group reported in this paper (60  9 years) and most were males (59%). From those who completed the
questionnaire, 34 subjects were from the Smoking Cessation Program (SCP) and 189 were from the case-finding group (59.02  9.07
and 61.02  11.01 years, respectively, p Z 0.13). The main reason for exclusion was the presence of a comorbid disease. Once
spirometry was performed, 48 subjects from the SCP and 100 from the case-finding group were, respectively, excluded because
they were unable to perform a valid spirometry. No differences in age and proportion of gender were observed between groups.
Early diagnosis of COPD 583used less frequently,22 is to screen all smokers, whether
asymptomatic or symptomatic. One may assume that, by
using the first strategy, a greater number of smokers with
COPD may be detected. However, recent studies have shown
that at least three or more symptoms are necessary in order
to detect approximately half of the number of smokers with
moderate to severe COPD.6,23 When smokers are preselected
on the basis of one symptom, the proportion of subjects with
an FEV1 <80% of predicted value is 27%.
7
These results suggest important limitations using the
strategy of testing only symptomatic smokers. By screening
all smokers, it has been assumed that the diagnosis andsubsequent prevalence significantly increases. Buffels
et al.24 found that screening with spirometry resulted in the
diagnosis of 7.4% of patients with previously unknown
COPD. Of these patients, 42% would not have been diag-
nosed without spirometry. These data, nevertheless,
underestimate the power of the screening because smoking
was not an inclusion criterion in the study. In another
screening study,25 the authors tested (using spirometry) all
outpatients with liver or general diseases and who were
>40 years old and regularly attended a hospital clinic,
finding a COPD prevalence of 8.7%. However, the sample
size was small.
Table 1 General characteristics, functional profile and
symptoms in smokers.
Variable Case-finding
(n Z 1999)
mean  SD
SCP group
(n Z 782)
mean  SD
p
Age (years) 52.6  9.6 46.8  12.1 <0.001
Male (%) 1007 (50.4) 377 (48.2) NS
Pack/years 20.4  18.4 30.6  23.4 <0.001
Cigarettes/day 13.9  9.9 20.3  10.9 <0.001
Years of smoking 27.9  11.0 29.7  11.9 <0.001
FEV1 ml 2.8  0.8 3.0  0.9 <0.001
FEV1%p 96.1  19.2 94.3  18.2 <0.020
FVC ml 3.5  0.9 3.8  1.0 <0.001
FVC%p 97.7  16.7 99.0  15.2 0.060
FEV1/FVC 80.1  9.8 78.2  9.4 <0.001
BMI 27.2 ± 4.4 26.1 ± 5.3 0.008
Diagnosis of COPD
according to
GOLD (%)
200 (10.1) 104 (13.3) 0.010
Diagnosis of COPD
according to
LLN (%)
154 (7.8) 91 (11.7) 0.001
Cough (%) 957 (49.6) 223 (29.3) <0.001
Phlegm (%) 1090 (56.2) 247 (32.4) <0.001
Wheezing (%) 695 (37.0) 68 (9.0) <0.001
Dyspnea (%) 1065 (56.0) 420 (55.0) 0.660
GOLD, global initiative for chronic obstructive lung disease;
SCP, smoking cessation program; LLN, lower limits of normal for
FEV1/FVC; BMI, body mass index.
Bold values indicate body mass index, lower limits of normal for
FEV1/FVC.
Table 2 General characteristics, functional profile and
symptoms in smokers with COPD.
Variable Case-finding
(n Z 200)
mean  SD
SCP group
(n Z 104)
mean  SD
p
Age (years) 60.8  10.1 58.7  9.8 0.120
Male (%) 120 (60.0) 57 (54.9) 0.380
Pack/years 36.2  29.9 47.7  38.4 <0.001
Cigarettes/day 19.2  12.7 22.5  14.7 0.040
Years of smoking 36.3  11.9 41.6  11.0 <0.001
FEV1 ml 1.8  0.7 2.1  0.8 <0.001
FEV1%p 65.4  22.5 70.6  20.9 0.050
FVC ml 3.1  1.0 3.4  1.2 0.030
FVC%p 87.5  21.1 92.2  21.7 0.070
FEV1/FVC 57.9  12.3 60.0  9.1 0.110
BMI 27.2 ± 4.4 26.0 ± 4.2 0.008
COPD diagnosis
according to
GOLD (%)
GOLD 1 57 (28.5) 38 (36.5) 0.230
GOLD II 92 (46) 49 (47.1)
GOLD III 35 (17.5) 13 (12.5)
GOLD IV 16 (8.0) 4 (3.8)
Cough (%) 120 (61.5) 37 (36.3) <0.001
Phlegm (%) 119 (60.4) 39 (38.2) <0.001
Wheezing (%) 110 (56.7) 15 (15.1) <0.001
Dyspnea (%) 137(70.6) 74 (72.5) 0.720
GOLD, global initiative for chronic obstructive lung disease;
SCP, smoking cessation program; BMI, body mass index.
Bold values indicate body mass index.
584 R.H. Sansores et al.The most recent and enlightening experience in regard
to screening studies is that reported by Zielinski and co-
workers in Poland26 who tested >100,000 smokers with
a cumulative consumption of 10 pack/years or higher and
who were >35 years of age. The authors found a total COPD
prevalence of 20.3%.
Together these studies suggest that the absence of
symptoms may mask diagnosis of COPD. In the PLATINO
study, the odds of underdiagnosis were significantly higher
among persons with fewer respiratory symptoms, suggest-
ing that many asymptomatic patients had COPD and the
probability for undergoing spirometry was lower in
comparison to symptomatic patients.4 In this sense,
screening with spirometry may be a useful instrument for
detecting smokers with COPD.
To the best of our knowledge, this is the first study
showing, simultaneously, both approaches for diagnosis of
COPD. It is interesting to note that the case-finding strategy
was successful in identifying symptomatic smokers. This
observation conflicts with the lower prevalence of COPD
reported by our group when diagnosis using spirometry is
encouraged only in the presence of symptoms in comparison
to that of screening all smokers. An explanation as to why
subjects from the case-finding group have more symptoms is
precisely due to the pre-selection according to symptoms,
whereas the higher prevalence of COPD in the screened
subjects from the SCP group is probably related to higher
tobacco consumption according to the pack/year index.Consistent with this finding, a recent meta-analysis showed
this causal relationship of a doseeresponse and increased
risk of COPD according to amount smoked and pack-years.27
No differences were found between variables described as
risk factors (age and gender) for developing COPD.20
Independent of the strategy used, a significant number
of smokers have benefitted from early diagnosis of COPD,28
especially those subjects with FEV1 >50%p. Early diagnosis
is particularly useful in smokers with COPD >50%, either
because they have symptoms that may be relieved or to
increase awareness for stopping smoking. The question at
this point is: What are the advantages of detecting subjects
with mild to moderate COPD? From the epidemiological
perspective, the risk of death is greater. For instance, from
a total of 15,440 adult participants in the ARIC study, after
adjusting for covariates,29 early stages of COPD predicted
a higher risk of death. In a more recent study,30 after
a mean follow-up of 26 years, subjects in GOLD stage I and
stage II had an increased risk of mortality. An interesting
finding was that in subjects with GOLD stage 0 with any
respiratory symptom, the hazard ratio (HR) for all-cause
mortality was 1.35 (p Z 0.03). In this sense, presence of
symptoms is related to a greater risk for developing
COPD31,32 and for mortality among male smokers with
normal pulmonary function (stage 0). In addition, according
to the cohort of De Marco et al.,33 subjects who reported
chronic cough/phlegm both at baseline and during follow-
up had an almost 3-fold increased risk of developing COPD
vs. asymptomatic subjects.
Table 3 Factors predictive of COPD diagnosis.
Variables Case-finding SCP group Case-finding þ SCP group
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.92 (0.89e0.93) <0.001 0.88 (0.85e0.91) <0.001 0.91 (0.89e0.92) <0.001
Gendera 1.5 (0.98e2.35) 0.050 2.03 (0.99e4.19) 0.050 1.70 (1.18e2.40) <0.001
Cough 1.24 (0.75e2.03) 0.390 3.63 (1.50e8.82) <0.001 1.69 (1.10e2.59) 0.010
Phlegm 0.67 (0.41e1.09) 0.110 1.07 (0.45e2.58) 0.86 0.79 (0.51e1.21) 0.280
Dyspnea 1.69 (1.06e2.69) 0.020 3.28 (1.65e8.83) <0.001 2.09 (1.41e3.1) <0.001
Wheezing 1.78 (1.13e2.79) 0.010 1.11 (0.43e2.84) 0.82 1.58 (1.07e2.32) 0.010
Multivariate logistic regression analysis for factors predicting COPD. Among the symptoms, only dyspnea predicts COPD by using either
strategy.
OR, odds ratio; CI, confidence interval.
SCP, Smoking Cessation Program.
a Reference category: female.
Early diagnosis of COPD 585In summary, despite current and updated GOLD guide-
lines that recommend case-finding studies for early diag-
nosis of COPD,34 the present study showed that a screening
program aimed at all smokers may also be a positive
strategy if economic resources are available. In this sense,
by considering that the GOLD report was aimed to positively
influence primary care physicians, these results may help
by offering additional tools of reflection. All lines of
evidence overwhelmingly demonstrate that the identifica-
tion of smokers (with or without symptoms) may also be
useful, not only to detect an important number of smokers
with COPD but also to increase awareness about COPD, to
prevent its development, to encourage smoking cessation
and to decrease the potential risk of death.
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